Skip to main content
. 2021 Nov 12;9(11):1317. doi: 10.3390/vaccines9111317

Table 2.

Vaccines licensed for use against COVID-19 [89,90].

Approach Vaccine Name Vaccine Class Manufacturer Efficacy Dosing and Storage
mRNA
vaccine
mRNA-
1273
Encapsulated mRNA Moderna/NIAID 94.1% against original strain 2 doses- 4 weeks apart
Stored at −20 °C
BNT162b2 Encapsulated mRNA BioNTech/Pfizer/Fosun Pharma 95% against original strain 2 doses- 3 weeks apart
Stored at −70 °C
Replication of defective
viral-vector vaccine
Ad5-nCoV Viral vector CanSino Biological in collaboration with Beijing Institute of Biotechnology and Academy of Military Medical Sciences Phase III (ongoing) 1 dose-
Stored at 2–8 °C
ChAdOx1
/AZD1222
Viral vector Oxford University/AstraZeneca 70.4% against original strain 2 doses- 4 weeks apart
Stored at 2–8 °C
Sputnik-V
/Gam-COVID-Vac
Viral vector Acellena Contract Drug Research and Development in collaboration with Gamaleya Research Institute and Health Ministry of the Russian Federation 91.4% against original strain 2 doses- 3 weeks apart
Stored at 2–8 °C
JNJ-78436735/
Ad26.COV2.S
Viral vector Johnson & Johnson 72% against original strain 1 dose-
Stored at 2–8 °C
Inactivated
vaccine
CoronaVac “
Sinovac”
Inactivated virus Sinovac Research and Development Co. 50% against original strain 2 doses- 2 weeks apart
Stored at 2–8 °C
BBIBP-CorV Inactivated virus Beijing Institute of Biotechnology 79.34% against original strain 2 doses- 3 weeks apart
Stored at 2–8 °C
Sinopharm
(Wuhan)
Inactivated virus China National Pharmaceutical Group (Sinopharm) in collaboration with Wuhan Institute of Biological Products undisclosed 2 doses- 3 weeks apart
Stored at 2–8 °C
BBV152/
Covaxin
Inactivated virus Bharat Biotech 81% against original strain 2 doses- 4 weeks apart
Stored at 2–8 °C
Subunit
vaccine
NVX-
CoV2373
Recombinant spike (rS)
and Matrix-M1 proteins
Novavax 96% against original strain 2 doses- 3 weeks apart
Stored at 2–8 °C
ZF2001 The repeated dimeric form of RBD of the SARS-CoV-2 S protein Anhui Zhifei Longcom/
Chinese Academy of Medicine
92–97% 3 doses- 4 weeks apart
Stored at 2–8 °C
Virus-like
particle (VLP)
CoVLP (NCT04450004) plant-produced VLP vaccine candidate expressing SARS-CoV-2 spike protein Medicago/GlaxoSmithKline Phase II–III clinical trial (ongoing) 2 doses- 3 weeks apart
Stored at 2–8 °C